Close Menu

licensing agreement

The point-of-care test is based on technology developed at the Columbia University Fertility Center for preimplantation genetic testing.

The expanded license from MIT includes clinical applications for the technology, with PathSensors initially targeting SARS-CoV-2 detection.

Developed by the Ragon Institute, the ELISA-based test measures antibodies that bind to the receptor binding domain of the SARS-CoV-2 spike protein.

BioSkryb will now have an exclusive global license for clinical applications of primary template directed amplification technology.

The novel blood test uses vibrational spectroscopy and metabolomic analysis to differentiate patients with fibromyalgia from those with other autoimmune disorders.

The technologies, called non-extensible oligonucleotides and linear DNA assembly, may help the sample prep firm improve existing products.

The May 8 settlement resolves all claims and counterclaims relating to noninvasive prenatal testing and pre-implantation genetic screening and diagnosis.

The partners are planning to develop and commercialize UroMap, a urine-based gene-expression test for acute cellular rejection in kidney transplant recipients.

Veracyte has obtained rights to a 52-gene signature developed by Yale researchers to predict disease progression in patients with idiopathic pulmonary fibrosis.

PharmaCyte, which develops therapies for cancer and diabetes, will be responsible for development and commercialization of tests based on the technology.

Pages